Listed by the USPTO as EBBINGHAUS, BRIANA NOEL
Tech Center 1600 • Art Units: 1613 1632
This examiner grants 60% of resolved cases
Briana Noel Ebbinghaus is an examiner in Tech Center 1600 and Art Unit 1613. She has 77 resolved cases. The allowance rate for these cases is 59.7 percent. The median time to allowance is 1448 days. This 1448-day timeline informs the expected duration of the prosecution process for applications that reach a grant. The 59.7 percent baseline helps practitioners estimate the likelihood of a successful outcome in this docket.
The interview lift is 63.0 percent. This 63.0 percent increase suggests that oral advocacy is an effective tool for overcoming rejections. Practitioners can use this metric to justify the time and resources required for an interview. Top companies in this docket include Precedo Pharmaceuticals Co. Ltd., Washington University, and Northwestern University. These companies are often represented by firms such as SCULLY SCOTT MURPHY & PRESSER, PC, Casimir Jones, S.C., and FOLEY & LARDNER LLP. These firms manage cases through the 1448-day median pendency to reach the 59.7 percent allowance rate. The 77 resolved cases provide a data set for evaluating examination trends in Art Unit 1613.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17054791 | RAAV VECTORS ENCODING OF LYSOSOMAL BETA-GALACTOSIDASE (GLB1) AND CATHEPSIN A | Final Rejection | University of Massachusetts |
| 17920599 | STEM CELL DERIVED SINGLE-ROSETTE BRAIN ORGANOIDS AND RELATED USES THEROF | Non-Final OA | The Regents of the University of Michigan |
| 18249865 | NUCLEIC ACID-GUIDED NUCLEASES AND USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17794166 | TRANSPOSON SYSTEMS FOR GENOME EDITING | Final Rejection | The Regents of the University of California |
| 19259714 | HUMAN SPINAL CORD INJURY ORGANOIDS | Non-Final OA | Northwestern University |
| 18735858 | HUMAN SPINAL CORD INJURY ORGANOIDS | Non-Final OA | Northwestern University |
| 18000414 | LARGE-SCALE PRODUCTION OF EXOSOMES FROM PRIMED MESENCHYMAL STROMAL CELLS FOR CLINICAL USE | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17755881 | NATURAL KILLER CELL IMMUNOTHERAPY FOR THE TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17603329 | CRISPR/CAS-BASED GENOME EDITING COMPOSITION FOR RESTORING DYSTROPHIN FUNCTION | Final Rejection | Duke University |
| 18010667 | SOMATIC STEM CELL-ACCUMULATED TISSUE CONSTRUCT AND DEVICE FOR PRODUCING THE SAME | Non-Final OA | BIOTUBE CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy59.7% of resolved applications examined by Briana Noel Ebbinghaus were allowed (77 resolved cases), compared with 34.0% across Art Unit 1613 over the last five years.
This examiner's interview lift is +63.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Briana Noel Ebbinghaus took 1,448 days on average from filing to allowance.
Briana Noel Ebbinghaus examines applications in Art Unit 1613 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
